

Currently Open Paediatric Haematology/Oncology Trials

Protocol Number	Protocol Name	Age Range	Criteria	Centre(s)
ACCT007	Phase I Study of Vinorelbine, Cyclophosphamide and Rapamycin for Recurrent Malignancies in Children	< 22 years	Solid tumour incl some CNS Must meet organ function and performance criteria	Starship Children's Hospital/ Christchurch Hospital
ALL SCTPed Forum	Allogeneic Stem Cell Transplantation (SCT) for Children and Adolescents with Acute Lymphoblastic Leukaemia (ALL)	< 18 years	ALL in first or any following CR with HR or VHR of recurrence of ALL	Starship Children's Hospital
ANZCHOG ASSET study	Acute Lymphoblastic Leukaemia Subtype and Side-Effects from Treatment (ASSET study)	≤ 18 years	Newly diagnosed ALL /MPAL	Starship Children's Hospital/ Christchurch Hospital
Future Fertility	FUTuRE Fertility - Australasian Oncofertility Registry	0-24 years	0-12 years: those who pursue fertility preservation; 13-24 years: all regardless of fertility input	Starship Children's Hospital/ Christchurch Hospital
Biogen PUPs A	A research study to find out if rFVIII Fc is safe and works well when taken by children and young adults with Haemophilia A	< 6 years	Severe haemophilia A previously untreated	Starship Children's Hospital/ Christchurch Hospital (via haemophilia centre)
Biogen PUPs B	A research study to find out if rFIX Fc is safe and works well when taken by children and young adults with Haemophilia B	< 18 years	Severe haemophilia B previously untreated	Starship Children's Hospital/ Christchurch Hospital (via haemophilia centre)
CCIA IMT study	Finding new treatments for ALK +ve inflammatory myofibroblastic tumours	All	Patients with IMT	Starship Children's Hospital
COG AALL08B1	Classification of newly diagnosed ALL	< 31 years	Newly diagnosed acute leukaemia (suspect lymphoblastic)	Starship Children's Hospital/ Christchurch Hospital
COG AALL0932	Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)	B-ALL: >365 days <10 years B-LLy: >365 days < 31 years	B-ALL: NCI Standard Risk; WCC <50000 B-Lly: Murphy Stage I-II Tissue submission	Starship Children's Hospital/ Christchurch Hospital
COG AALL1131	A Phase III Randomised Trial for Newly Diagnosed High Risk B-precursor ALL testing Clofarabine in the Very High Risk Stratum	> 365 days - < 31years	Age: >365 days - < 10 years: WCC ≥ 50000 Age: ≥ 10 years - < 31years: Any WCC Any age: Any WCC + Testicular involvement, CNS 3 or steroid pre-treatment per protocol	Starship Children's Hospital/ Christchurch Hospital
COG AALL1231	A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL)and T- Lymphoblastic Lymphoma (T-LLy)	> 365 days - < 31years	Newly diagnosed T-ALL / T-Lly; must enrol on AALL08B1; no prior therapies	Starship Children's Hospital/ Christchurch Hospital
COG AALL1331	Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)	≥1 year and < 31 years of age at the time of relapse	First relapse B-ALL; must meet organ function and prior therapy criteria; tissue submission requirements	Starship Children's Hospital/ Christchurch Hospital
COG AAML1031	A Phase III Randomised Trial for Patients with de novo AML using Bortezomib and Sorafenib for Patients with High Allelic Ratio FLT3/ITD	< 30 years	De novo AML	Starship Children's Hospital/ Christchurch Hospital
COG AAML1331	A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid	≥ 12 months and < 22 years of age	de novo APL	Starship Children's Hospital/ Christchurch Hospital
COG ABTR01B1	Collecting and Banking Paediatric Research Specimens including Rare Paediatric Tumours	≤ 30 years	Specimen submission per protocol	Starship Children's Hospital

This list is current at the time of posting and will be updated in May and November each year

Currently Open Paediatric Haematology/Oncology Trials

COG ACNS02B3	CNS Banking Study	No age restrictions	Specimen submission per protocol	Starship Children's Hospital
COG ACNS0831	Ependymoma Newly Diagnosed	1year - 21 years	Histologically confirmed intracranial ependymoma non-metastatic	Starship Children's Hospital
COG ACNS1022	A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytoma and Optic Pathway Gliomas	< 22 years	Must have measurable disease Must meet performance and organ function criteria Strict mandatory contraception advice processes	Starship Children's Hospital/ Christchurch Hospital
COG ACNS1123	Phase II Trial of Response-based Radiation Therapy for Patients with Localised CNS Germ Cell Tumours	≥ 3 years - ≤ 21 years	Newly diagnosed, localised disease	Starship Children's Hospital/ Christchurch Hospital
COG AEP110N5	Genetic Epidemiology of Ewing Sarcoma	Any	Must have at least one biological parent willing to participate Requires submission of saliva and medical/family history information. Will be run via key	Starship Children's Hospital/ Christchurch Hospital
COG AEWS07B1	Ewing Tumour Biology and Banking Study	No age restrictions	Specimen submission per protocol	Starship Children's Hospital
COG AEWS1031	A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma	≤ 50 years	Histologically confirmed Ewing's of bone or soft tissue No previous chemotherapy No abnormal cardiac or renal function	Starship Children's Hospital/ Christchurch Hospital
COG ANBL00B1	Neuroblastoma biology studies	No age restrictions	Specimen submission per protocol	Starship Children's Hospital/ Christchurch Hospital
COG ANBL1232	Utilizing Response and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma	< 18 months	Includes only some subgroups of Non-HR neuroblastoma; must enrol on ANBL00B1	Starship Children's Hospital/ Christchurch Hospital
COG ANBL1221	Phase II Trial of Irinotecan/Temozolamide with Temozolamide or Ch 14.18 in Children with Relapsed, Refractory or Progressive Neuroblastoma	No age restrictions	Histological diagnosis of neuroblastoma or ganglioneuroblastoma at diagnosis or recurrence; measurable disease; first episode of recurrence or progression	Starship Children's Hospital/ Christchurch Hospital
COG AOST06B1	Collecting and Banking Osteosarcoma Specimens	No age restrictions	Specimen submission per protocol	Starship Children's Hospital
COG AOST1421	Phase II trial of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 in Combination with GM-CSF and Interleukin-2 in Patients with Recurrent Osteosarcoma	< 30 years	Resectable pulmonary recurrence; no distal bone recurrence; no concurrent pulmonary and local recurrence; no primary refractory (must be in CR within 4 weeks prior to enrolment); must meet physiological parameters.	Starship Children's Hospital/ Christchurch Hospital
COG APEC14B1	Project Everychild: A Registry, Eligibility Screening, Biology and Outcome Study	≤ 25 years at original dx unless eligibility criterion for open therapy study.	All cancers including LCH and borderline malignancies such as those included in NZCCR	Starship Children's Hospital/ Christchurch Hospital
COG AREN03B2	Renal Tumour Classification, Banking and Biology Study	< 30 years	Specimen submission per protocol	Starship Children's Hospital/ Christchurch Hospital
COG D9902	Soft Tissue Sarcoma Biology and Banking	≤ 50 years	Specimen submission per protocol	Starship Children's Hospital/ Christchurch Hospital
EuroNET PHL-C2	Second International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents	< 25 years	Newly diagnosed classical HL, histologically confirmed. Tissue submission requirements.	Starship Children's Hospital/ Christchurch Hospital (pending)
Interfant-06	Infant ALL	Up to 365 days	Newly diagnosed ALL / biphenotypic leukaemia	Starship Children's Hospital/ Christchurch Hospital
IntReALL	International Study of Treatment of Standard Risk Childhood Relapsed ALL 2010	< 18 years	SR relapsed ALL; tissue submission requirements	Starship Children's Hospital/ Christchurch Hospital

This list is current at the time of posting and will be updated in May and November each year

Currently Open Paediatric Haematology/Oncology Trials

LCH IV	International Collaborative Treatment Protocol for Children and Adolescents with LCH	< 18 years	Confirmed dx of LCH	Starship Children's Hospital/ Christchurch Hospital
MSD Keytruda	Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)	0-18 years	Advanced melanoma or PD-L1 +ve advanced, relapsed solid tumours/lymphoma	Starship Children's Hospital
Ovarian Tissue Protocol	Ovarian Tissue Cryopreservation/Banking Protocol for New Zealand Paediatric Haematology/Oncology Services	0-18 years	Must meet disease, prognosis and risk criteria per protocol	Starship Children's Hospital/ Christchurch Hospital (pending)
SJMB12	A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed medulloblastoma	≥ 3 years and < 22 years	Confirmed dx of medulloblastoma; tissue submission requirements; no prior therapy	Starship Children's Hospital

This list is current at the time of posting and will be updated in May and November each year